No Price Stabilization or Manipulation; Compliance with Regulation M. None of the Company, any of the Subsidiaries or any of their respective directors, officers or affiliates has taken, directly or indirectly, any action designed, or which has constituted or might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares in violation of Regulation M under the Exchange Act. The Company acknowledges that the Agent may engage in passive market making transactions in the Shares on the Nasdaq Global Market in accordance with Regulation M. The Common Shares are “actively traded securities” (as defined in Regulation M).
Appears in 3 contracts
Samples: Open Market Sale Agreement (Selecta Biosciences Inc), Open Market Sale Agreement (Selecta Biosciences Inc), Sales Agreement (Selecta Biosciences Inc)
No Price Stabilization or Manipulation; Compliance with Regulation M. None of Neither the Company, Company nor any of the Subsidiaries or any of their respective directors, officers or affiliates its subsidiaries has taken, directly or indirectly, any action designed, designed to or which has constituted or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of the Common Shares or of any security “reference security” (as defined in Rule 100 of Regulation M under the Company Exchange Act (“Regulation M”)) with respect to the Shares, whether to facilitate the sale or resale of the Shares in violation of or otherwise, and has taken no action which would directly or indirectly violate Regulation M under the Exchange Act. M. The Company acknowledges that the Agent may engage in passive market making transactions in the Shares on the Nasdaq Global Market in accordance with Regulation M. The As of the date hereof, the Common Shares are “actively traded securities” (as defined in Regulation M).
Appears in 2 contracts
Samples: Open Market Sale Agreement (Minerva Neurosciences, Inc.), Open Market Sale Agreement (Minerva Neurosciences, Inc.)
No Price Stabilization or Manipulation; Compliance with Regulation M. None Neither the Company nor any of its subsidiaries nor, to the Company’s knowledge, any of the Subsidiaries or any of their respective directorsofficers, officers directors or affiliates has takentaken or will take, directly or indirectly, any action designeddesigned to or intended to stabilize or manipulate the price of any security of the Company, or which has constituted caused or might resulted in, or which would in the future reasonably be expected to cause or result in the stabilization or manipulation of the price of the Common Shares or any security other “reference security” (as defined in Rule 100 of Regulation M under the Company Exchange Act (“Regulation M”)) whether to facilitate the sale or resale of the Shares in violation of or otherwise, and has taken no action which would directly or indirectly violate Regulation M under the Exchange Act. M. The Company acknowledges that the Agent may engage in passive market making transactions in the Shares on the Nasdaq Global Principal Market in accordance with Regulation M. The Common Shares are “actively traded securities” (as defined in Regulation M).
Appears in 1 contract
Samples: Open Market Sale Agreement (Aldeyra Therapeutics, Inc.)
No Price Stabilization or Manipulation; Compliance with Regulation M. None of Neither the Company, Company nor any of the Subsidiaries or any of their respective directors, officers or affiliates its subsidiaries has taken, directly or indirectly, any action designed, designed to or which has constituted or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of the Common Stock or of any security “reference security” (as defined in Rule 100 of Regulation M under the Company Exchange Act (“Regulation M”)) with respect to the Common Stock, whether to facilitate the sale or resale of the Placement Shares in violation of Regulation M under the Exchange Act. The Company acknowledges that the Agent may engage in passive market making transactions in the Shares on the Nasdaq Global Market in accordance with or otherwise, and has taken no action which would directly or indirectly violate Regulation M. The Common Shares Stock are “actively traded securities” (as defined in Regulation M).
Appears in 1 contract
Samples: Open Market Sale Agreement (Abeona Therapeutics Inc.)
No Price Stabilization or Manipulation; Compliance with Regulation M. None of Neither the Company, Company nor any of the Subsidiaries or any of their respective directors, officers or affiliates its subsidiaries has taken, directly or indirectly, without giving effect to activities by the Agent, any action designed, designed to or which has constituted or might that would reasonably be expected to cause or result in the stabilization or manipulation of the price of the Common Shares or of any security “reference security” (as defined in Rule 100 of Regulation M under the Company Exchange Act (“Regulation M”)) with respect to the Common Shares, whether to facilitate the sale or resale of the Shares in violation of Regulation M under the Exchange Act. The Company acknowledges that the Agent may engage in passive market making transactions in the Shares on the Nasdaq Global Market in accordance with or otherwise, and has taken no action which would directly or indirectly violate Regulation M. The Common Shares are “actively traded securities” (as defined in Regulation M).
Appears in 1 contract
Samples: Open Market Sale Agreement (Bellicum Pharmaceuticals, Inc)
No Price Stabilization or Manipulation; Compliance with Regulation M. None Neither the Company nor any of its subsidiaries nor, to the Company’s knowledge, any of the Subsidiaries or any of their respective directorsofficers, officers directors or affiliates Affiliates has takentaken or will take, directly or indirectly, any action designeddesigned to or intended to stabilize or manipulate the price of any security of the Company, or which has constituted caused or might resulted in, or which would in the future reasonably be expected to cause or result in the stabilization or manipulation of the price of the Common Shares or any security other “reference security” (as defined in Rule 100 of Regulation M under the Company Exchange Act (“Regulation M”)) whether to facilitate the sale or resale of the Shares in violation of or otherwise, and has taken no action which would directly or indirectly violate Regulation M under the Exchange Act. M. The Company acknowledges that the Agent may engage in passive market making transactions in the Shares on the Nasdaq Global Principal Market in accordance with Regulation M. The Common Shares are “actively traded securities” (as defined in Regulation M).
Appears in 1 contract
Samples: Open Market Sale Agreement (Aldeyra Therapeutics, Inc.)